| 86.91 Delayed Data As of Aug 21 |  +1.26 / +1.47%Today’s Change | 66.10 Today|||52-Week Range 87.25 | +13.74% Year-to-Date |
| Previous close | 85.65 |
| Today’s open | 86.29 |
| Day’s range | 86.13 - 87.25 |
| Volume | 6,188,981 |
| Average volume (3 months) | 10,656,633 |
| Market cap | $217.4B |
| Earnings growth (last year) | +165.32% |
| Earnings growth (this year) | +12.84% |
| Earnings growth (next 5 years) | +9.00% |
| Revenue growth (last year) | +6.17% |
| P/E ratio | 24.3 |
| Price/Sales | 4.82 |
| Price/Book | 8.25 |
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | +1.04 | +1.17% |
| PFEPfizer | +0.26 | +0.75% |
| AZNAstraZeneca | +0.80 | +1.79% |
| LLYEli Lilly and Co | +0.45 | +0.41% |
| Next reporting date | October 29, 2019 |
| EPS forecast (this quarter) | $1.25 |
| Annual revenue (last year) | $42.4B |
| Annual profit (last year) | $6.2B |
| Net profit margin | 14.65% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman, President & Chief Executive Officer Kenneth C. Frazier |
CFO & Executive Vice President-Global Services Robert M. Davis |
Corporate headquarters Kenilworth, New Jersey |
